After decades of research, finally a therapeutic innovation against pancreatic cancer

A significant breakthrough in the fight against pancreatic cancer, one of the most aggressive forms of the disease, was presented at the American Society of Clinical Oncology (ASCO) congress in Chicago. Thousands of oncologists and researchers gave a standing ovation to the results of an international Phase III trial assessing a new therapy, daraxonrasib.

For years, pancreatic cancer has resisted therapeutic advances seen in other aggressive cancers. "Over the last ten years, there have been major innovations for many cancers with poor prognoses, but unfortunately nothing for pancreatic tumors, which remain among the most aggressive," said Dr. Thibaud Kössler, head of the digestive tumor unit at the University Hospitals of Geneva (HUG).

The trial evaluated daraxonrasib for patients with metastatic pancreatic cancer. The results showed that the new molecule performed better than chemotherapy in second-line treatment, meaning for patients whose disease progressed despite initial chemotherapy. This marks a crucial step forward in offering new hope to patients battling this devastating illness.

“

Over the last ten years, there have been major innovations for many cancers with poor prognoses, but unfortunately nothing for pancreatic tumors, which remain among the most aggressive. The results obtained with daraxonrasib finally show an advance; a molecule that does better than chemotherapy in second line, that is to say for patients whose disease progresses despite a first line of chemotherapy.